WO1999043736A1 - Polymeres transporteurs migrant dans des organes cibles et polymeres contenant des medicaments - Google Patents
Polymeres transporteurs migrant dans des organes cibles et polymeres contenant des medicaments Download PDFInfo
- Publication number
- WO1999043736A1 WO1999043736A1 PCT/JP1999/000872 JP9900872W WO9943736A1 WO 1999043736 A1 WO1999043736 A1 WO 1999043736A1 JP 9900872 W JP9900872 W JP 9900872W WO 9943736 A1 WO9943736 A1 WO 9943736A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polymer
- group
- drug
- general formula
- represented
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/48—Polymers modified by chemical after-treatment
Definitions
- the present invention relates to a sugar-modified polymer useful as a carrier (carrier) capable of moving to a target organ (cell), a drug-containing polymer using the same, and a method for producing the same.
- a drug utilizing galactose's specific receptor in liver parenchymal cells can be used to combine galactose with protein or synthetic polymer. It is described that the compound is modified with a compound in which the compound is combined with the compound to improve the ability to enter the liver.
- X a has a degree of polymerization of 20 to 540, and R a represents hydrogen, lower alkyl, or benzyl group.
- R a represents hydrogen, lower alkyl, or benzyl group.
- polymer PA A polymer of a PGE! -Containing L-glutamic acid derivative (hereinafter, referred to as polymer PA) represented by the following formula is described as a polymerized prodrug for the purpose of enhancing the liver-localization of PGE !.
- the drug (PGE) and L_glutamic acid are linked via an amide bond with ethylenediamine (—NH—CH 2 CH 2 _NH—) as a spacer.
- the present inventors use hydrazine (—NH—NH—) instead of ethylenediamine (_NH—CH 2 CH 2 —NH—) as a spacer to bind a drug (eg, PGEi) to L-glutamic acid.
- a drug eg, PGEi
- the degree of accumulation of the drug in the liver after administration is higher in the polymer of the present invention using hydrazine than in the polymer using ethylenediamine, and is superior in terms of drug efficacy (the hepatocyte protective action of PGE!).
- the present invention is a.
- R is a hydrogen atom, C1-6 alkyl Or a benzyl group. However, a plurality of Rs may be the same or different. ) Part or all of the constituent peptide bonds of poly-L-glutamic acid represented by the general formula
- G represents a saccharide CC CNGNMIIII modified to be able to bind to hydrazine
- m is 1 when I is a single bond, and is 0 when I is a double bond.
- the groups represented by the general formulas (B) and (C) are essential substituents, and the number of the substituents represented by the general formula (C) is 2 or more.) In this case, all the groups are the same.
- a polymer substituted with hereinafter referred to as a polymer — P 1),
- NHn is NH or N
- the polymer P1 is a carrier polymer having a transfer property to a target organ (cell)
- the polymer P2 is a drug-containing polymer having a transfer property to a target organ (cell) using the polymer.
- the transportability of the polymer of the present invention to a target organ (cell) depends on a saccharide (represented by G) bound to glutamic acid. It is known that organs (cells) have receptors for various saccharides.
- the saccharide (G) that binds depending on the target organ (cell), including the body, can be selected to achieve migration to the target organ (cell).
- galactose receptor in the case of monosaccharides, galactose receptor, mannose receptor, and fucose receptor are hepatic parenchymal cells, hepatic nonparenchymal cells (endothelial cells and Kupfier cells) and Kupffer cells, respectively.
- galactokinase 1 scan, mannose, fucose body (the present invention the polymer one P l, formula described later is Hm that put the P 2 (G 1), corresponding to (G 2), (G 3 ) G)
- the liver (each cell of the liver) can be transferred.
- the translocation to the target organ depends on the type of the terminal sugar.
- disaccharide lactose the polymer of the present invention
- a natural product can be used or can be artificially synthesized.
- d represents the degree of polymerization of L-glutamic acid, which is a constitutional unit of the polymer of the present invention, and is an integer of 20 to 500. Preferably, it is an integer of 40 to 300, more preferably, an integer of 50 to 150.
- Substituent number of groups represented by the general formula (B) is 5 to 250, preferably, Ru 5-50 Kodea.
- Substituent number of groups represented by (C) are. 10 to: L is 00, preferably, 20 to 60 pieces.
- the number of substitution of the group represented by the general formula (B) (corresponding to y described later) is from 0 to 250, and preferably from 0 to 50.
- substituent number of groups represented by (C) (you corresponding to z 3 to be described later.) Is 10 to 100, preferably 20 to 60 pieces.
- the number of substituents of the group represented by the general formula (D) (corresponding to w 3 described later) is 1
- 2020 preferably 1 to: L0.
- the average molecular weight of the polymer P1 is between 5,000 and 150,000.
- monosaccharide I monosaccharide I
- t Hm corresponds to the formulas (G 1 ), (G 2 ), and (G 3 ) described below.
- a disaccharide such as a G-lactose body (the formulas ( G 4a), ( G 5a )
- the average molecular weight of the polymer P1 is from 5,000 to 100,000, preferably from 10,000 to 30,000.
- the C1-6 alkyl represented by R includes methyl, ethyl, propyl, butyl, pentyl, hexyl groups and isomers thereof.
- R For each R, i) a combination of hydrogen and the above-mentioned C 1-6 alkyl group (all alkyl groups are the same), ii) a combination of hydrogen and benzyl, or iii) a case of only hydrogen And more preferably iii) the case of only hydrogen.
- the saccharide represented by G can be selected according to a known receptor present in an organ (cell) or a receptor identified in a future study as described above.
- Examples of the saccharide modified to be capable of binding to hydrazine represented by G include a 2-iminoethyl-1-thiosaccharide, a saccharide containing a saccharide that is cleaved in the group, and the like.
- Q represents a sugar chain having 1 to 10 sugars.
- the saccharide represented by 1 to 10 represented by Q is, for example, a general formula
- the drug represented by D may be any drug, but is preferably a substance that is unstable under alkaline conditions. As such alkaline conditions, pH 8 to 11 is preferable. Of course, it can be applied to drugs other than drugs that are unstable under alkaline conditions.
- Specific drugs include PGs (eg, PGEs, PGFs, PGDs), PGIs, naphthyloxyacetic acid derivatives, bicycloalkanoic acid derivatives, guanidinobenzoic acid derivatives, rhodaninacetic acid derivatives, cinnamic acid derivatives, valproic acid Inducers, vitamins, antiallergic agents, antibiotics, anticancer agents and the like.
- PG compounds PGE have PGE 2, PGF i a as, PGF 2 a, P GDj, include natural PG and their derivatives, such as PGD 2.
- (PGEi) is a compound represented by (PGE 2 ), and PGD ⁇ PGD;
- R e represents a hydrogen atom or various substituents of a C 1-12 alkyl or benzyloxy group such as benzyl,
- A is a C2-10 alkylene group, (1) any carbon atom in the group may be replaced by a carbonyl group, and Z or (2) having one or more double bonds.
- B is a phenyl, phenoxy or cycloalkyl group (each ring in the group has various substituents such as C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, halogen, etc.
- C which may be substituted by Represents an! -10 alkyl, C2-10 alkenyl or C2-10 alkynyl group;
- ⁇ represents ethylene, trans-vinylene or ethynylene.
- Such compounds include:
- PGE PGE 2 17,20-dimethyl-trans- ⁇ 2 — PGE 6-keto—17,20-dimethyl-trans— Methyl ester, 16, 16 Jimechiru - trans - delta 2 -! PGE methyl ester, and the like et be.
- PGFs bind to L-glutamic acid via an amide bond between the hydroxyl group in the group and the hydrazine amide.
- PGIs examples include natural PGI 2 and derivatives thereof, and examples thereof include compounds described in JP-A-54-130543 and JP-A-55-64541 (corresponding British Patent No. 2017699). PGIs also bind to L-daltamate via an amide bond.
- naphthyloxyacetic acid derivative examples include compounds described in JP-A-6-87811 (corresponding US Pat. No. 5,480,998).
- Such a naphthyloxyacetic acid compound has the following structural formula
- Bicycloalkanoic acid derivatives include, for example, compounds described in Japanese Patent Application No. 9-140959.
- Examples of the guanidinobenzoic acid derivative include compounds described in JP-A-51-138642 (corresponding to U.S. Pat. No. 4021472).
- rhodanin acetic acid derivative examples include compounds described in JP-A-57-40478 (corresponding US Pat. No. 4,464,382).
- Examples of cinnamic acid derivatives include: 1) JP-A-55-313 (corresponding U.S. Pat. No. 4,226,878), 2) JP-A-57-131769 (corresponding U.S. Pat. No. 4,607,046), 3) International Application No. PCT / JP97 / 04593.
- valproic acid derivative examples include compounds described in JP-A-7-316092 (European Publication 0632008A1).
- the polymer of the present invention can be produced by a method described in Examples described later, a known method, or a reaction of (1) to (3) described below.
- d 1, x 1 and y 1 are, COOR 1 (wherein each, R 1 represents a C L ⁇ 67 alkyl or benzyl group.), C_ ⁇ _OH, 1 ⁇ 11 2 are bonded 1 ⁇ —Denotes the number of moles of glumic acid (degree of polymerization), where (1) the sum of d 1 X 1 and y 1 is the same as d, (2) d 1 may be 0, or (3 ) COOR 1
- 2-imino-2-methoxyethyl-1-thiosaccharide is reacted under a weak base condition (for example, in a borate buffer (pH 9 to 10)), or (b) a polymer represented by the general formula (II) and various kinds of
- the saccharide (G) can be bound to the hydrazine in the polymer represented by the general formula (II) by reacting the saccharide with a saccharide and, if necessary, subjecting the saccharide to a reduction reaction.
- 2-imino-2-methoxyethyl-1 -thiogalactoside 2-imimino-2-methoxyxethyl-11-thiomannoside or 2-imino-2-methoxyethyl-1-thiofucoside.
- the 2-imino-2-methoxyethyl-1-thiosaccharide is known or the cyanomethyl-1-thiosaccharide is dissolved in methanol in sodium G NG NMMM that can be produced by reacting with toxide at room temperature (10 to 25 ° C)
- This reduction reaction is a reaction called reductive amination, and uses a reducing agent such as sodium borohydride or sodium cyanoborohydride under weak base conditions (for example, in a borate buffer (pH 8 to 9)). At 30-50 ° C. Similarly, common saccharides can be bound to hydrazine.
- the saccharide (G) can be bound to the hydrazine in the polymer represented by the general formula (II) by using a known reaction other than the above-mentioned reactions (a) and (b).
- the general formula (1-1) the general formula (1-1)
- d 2 , x 2 , y 2 and z 2 are each COOR 1 (wherein R 1 has the same meaning as described above), CO ⁇ H, NH 2 , and G (saccharide) L—Denotes the number of moles of glutamic acid (degree of polymerization), where (1) the sum of d 2 , x 2 , y 2 and z 2 is the same as d, and (2) d 2 is 0 (3) COOR 1 (wherein, R 1 has the same meaning as described above), CO ⁇ H, NH 2 , G
- sequence order of the individual L-glutamic acids to which the (saccharide) is bound is arbitrary. ) (Corresponding to the above-mentioned polymer P1).
- reaction (3) various reactions are performed depending on the structure of the drug.
- a hydrazone bond can be formed by a dehydration-condensation reaction with hydrazine in a polymer represented by the general formula (1-1). This reaction is carried out under mildly acidic conditions (eg, citrate buffer (PH4 ⁇ 6) Medium) at room temperature (10 ⁇ 25 ° C).
- mildly acidic conditions eg, citrate buffer (PH4 ⁇ 6) Medium
- an amide bond can be formed by an amidation reaction with a terminal amino group of hydrazine in the polymer represented by the general formula (1-1).
- This reaction is a known reaction, for example,
- a drug can be introduced into poly L-glutamic acid by forming various bonds by using a known method.
- the same saccharide as the saccharide introduced in the reaction (2) is reacted again with the polymer produced in the reaction (3), whereby NH 2 of the hydrazine in the group can be cabbed with the saccharide.
- d 3 , x 3 , y 3 , z 3 and w 3 each represent COOR 1 (wherein R 1 has the same meaning as described above), C ⁇ H, NH 2 , G (saccharide ) Represents the number of moles of L-glutamic acid (degree of polymerization) to which D (drug) is bound, provided that (1) the sum of d 3 , x 3 , y 3 , z 3 and w 3 is the same as d , (2) d 3 and y 3 may be independently 0, (3) COOR 1 (wherein R 1 has the same meaning as described above) Represents ), C ⁇ H, NH 2 , G (sugar), D (drug) bound to each L-glutamic acid can be in any order.
- the present invention-containing polymer (corresponding to polymer P2 described above) represented by the following formula (1) can be produced.
- the reaction product is purified by conventional purification means such as dialysis, distillation under normal pressure or reduced pressure, high performance liquid chromatography using silica gel or magnesium gayate, thin-layer chromatography, or column chromatography. It can be purified by a method such as chromatography, washing, or recrystallization. Purification may be performed for each reaction, or may be performed after several reactions.
- conventional purification means such as dialysis, distillation under normal pressure or reduced pressure, high performance liquid chromatography using silica gel or magnesium gayate, thin-layer chromatography, or column chromatography. It can be purified by a method such as chromatography, washing, or recrystallization. Purification may be performed for each reaction, or may be performed after several reactions.
- the starting materials and reagents used in the present invention are known per se or can be produced by known methods. Industrial applicability
- the transferability to the target organ was confirmed for the polymer of the present invention, which is described as polymer P1, as shown in the experimental examples described later.
- the polymer is a polyamino acid that is a high-molecular-weight molecule similar to nature, so it is expected to be a biodegradable and highly safe polymer. Therefore, the polymer is useful as a carrier.
- the drug-containing polymer of the present invention represented as polymer P2 also has excellent drug efficacy because of its ability to migrate to target organs, as shown in the experimental examples described below.
- HZ hydrazine
- ED ethylenediamine
- PGEi- PGEi partially bound with 3 H among PGEi bound to hydrazine or ethylenediamine
- Gal 1 _ thiogalactobilanosyl-2-iminoethyl
- PLGA-HZ-Ga 1 (manufactured in Example 3) and PLGA-HZ-Lac (manufactured in Example 5) were labeled with 111 In , and each was administered at a dose of 1 mg g in the mouse tail vein. And its biodistribution characteristics were examined. The results are shown in Tables 1 and 2. (The figures in the tables are the percentage remaining per ml of plasma at each time point after administration, the percentage of reaching the organ, and the percentage of urinary recovery (mean Soil deviation). Table 1: Pharmacokinetics of PLGA—HZ_Ga1
- the polymer containing the drug of the present invention (PGE) Significantly suppressed the increase in plasma GPT value in carbon tetrachloride-induced liver injury as compared with saline (control group). Also, it can be seen that the rate of suppression of the increase in GPT was improved by a factor of 3 compared to the group receiving the corresponding amount of free PGE !.
- 5 Omg was dissolved in 5 N sodium hydroxide, and the pH was adjusted to around 7 with 5 N hydrochloric acid.
- Add 1M borate buffer (pH 8.5) check that the pH is 8-9, add lactose (143 mg) and sodium cyanoborohydride (5 Omg), and add The reaction was carried out overnight at ° C.
- the reaction solution was purified by dialysis and lyophilized to give the title compound having the following physical data.
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99906483A EP1065233A1 (en) | 1998-02-27 | 1999-02-25 | Carrier polymers migrating into target organs and drug-containing polymers |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6483398 | 1998-02-27 | ||
JP10/64833 | 1998-02-27 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/623,136 A-371-Of-International US6500916B1 (en) | 1998-02-27 | 1999-03-02 | Carrier polymers migrating into target organs and drug-containing polymers |
US10/283,047 Division US20030104989A1 (en) | 1998-02-27 | 2002-10-30 | Carrier polymers migrating into target organs and drug-containing polymers |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999043736A1 true WO1999043736A1 (fr) | 1999-09-02 |
Family
ID=13269653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/000872 WO1999043736A1 (fr) | 1998-02-27 | 1999-02-25 | Polymeres transporteurs migrant dans des organes cibles et polymeres contenant des medicaments |
Country Status (4)
Country | Link |
---|---|
US (2) | US6500916B1 (ja) |
EP (1) | EP1065233A1 (ja) |
KR (1) | KR20010041358A (ja) |
WO (1) | WO1999043736A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006115293A1 (ja) * | 2005-04-22 | 2006-11-02 | The University Of Tokyo | pH応答性高分子ミセルの調製に用いる新規ブロック共重合体及びその製造法 |
JP2007191643A (ja) * | 2006-01-20 | 2007-08-02 | Mitsui Chemicals Inc | 生体への定着性が付与されたポリアミノ酸誘導体 |
WO2008007650A1 (fr) * | 2006-07-14 | 2008-01-17 | Otsuka Chemical Co., Ltd. | résine d'accumulation de l'hydrazine |
US8436026B2 (en) | 2002-10-10 | 2013-05-07 | Ono Pharmaceutical Co., Ltd. | Endogeneous repair factor production promoters |
JP2016520124A (ja) * | 2013-05-27 | 2016-07-11 | バイオリーダーズ コーポレーションBioleaders Corporation | ポリ−γ−グルタミン酸を含有する粘液分散または水和用組成物 |
JP2016520123A (ja) * | 2013-05-31 | 2016-07-11 | バイオリーダーズ コーポレーションBioleaders Corporation | 粘膜粘着性ポリ−γ−グルタミン酸ナノミセルおよびこれを用いた薬物伝達体 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050276783A1 (en) * | 2004-06-10 | 2005-12-15 | Ernest Giralt Lledo | Polypeptides with the capacity to entrap drugs and release them in a controlled way |
US20070134335A1 (en) * | 2005-06-08 | 2007-06-14 | Lledo Ernest G | Polypeptides with the capacity to entrap drugs and release them in a controlled way |
ES2435773T3 (es) | 2005-09-02 | 2013-12-23 | The Procter & Gamble Company | Personalización de aroma para lavado de ropa |
US20080248097A1 (en) * | 2007-02-26 | 2008-10-09 | Kwon Glen S | Polymeric micelles for combination drug delivery |
US20090232762A1 (en) * | 2008-03-11 | 2009-09-17 | May Pang Xiong | Compositions for delivery of therapeutic agents |
WO2011038278A2 (en) | 2009-09-25 | 2011-03-31 | Wisconsin Alumni Research Foundation | Micelle encapsulation of therapeutic agents |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05508879A (ja) * | 1990-07-06 | 1993-12-09 | エンゾン・インコーポレイテッド | ポリ(アルキレンオキサイド)アミノ酸コーポリマ並びにこれに基づく薬剤キャリアおよび帯電コーポリマ |
JPH0687811A (ja) * | 1992-07-21 | 1994-03-29 | Ono Pharmaceut Co Ltd | オキシム誘導体、その製造方法およびそれを含有する医薬品 |
JPH07228688A (ja) * | 1994-02-18 | 1995-08-29 | Yamanouchi Pharmaceut Co Ltd | 糖修飾ポリ−ω−置換−L−グルタミン酸誘導体およびその製造方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3985617A (en) * | 1974-10-29 | 1976-10-12 | Ajinomoto Co., Inc. | Immobilization of biologically active proteins with a polypeptide azide |
US4371673A (en) * | 1980-07-21 | 1983-02-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble forms of retinoids |
US5650270A (en) * | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
WO1992000748A1 (en) | 1990-07-06 | 1992-01-23 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
-
1999
- 1999-02-25 WO PCT/JP1999/000872 patent/WO1999043736A1/ja not_active Application Discontinuation
- 1999-02-25 KR KR1020007009474A patent/KR20010041358A/ko not_active Application Discontinuation
- 1999-02-25 EP EP99906483A patent/EP1065233A1/en not_active Withdrawn
- 1999-03-02 US US09/623,136 patent/US6500916B1/en not_active Expired - Fee Related
-
2002
- 2002-10-30 US US10/283,047 patent/US20030104989A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05508879A (ja) * | 1990-07-06 | 1993-12-09 | エンゾン・インコーポレイテッド | ポリ(アルキレンオキサイド)アミノ酸コーポリマ並びにこれに基づく薬剤キャリアおよび帯電コーポリマ |
JPH0687811A (ja) * | 1992-07-21 | 1994-03-29 | Ono Pharmaceut Co Ltd | オキシム誘導体、その製造方法およびそれを含有する医薬品 |
JPH07228688A (ja) * | 1994-02-18 | 1995-08-29 | Yamanouchi Pharmaceut Co Ltd | 糖修飾ポリ−ω−置換−L−グルタミン酸誘導体およびその製造方法 |
Non-Patent Citations (1)
Title |
---|
AKAMATSU K, ET AL.: "SYNTHESIS AND BIODISTRIBUTION STUDY OF LIVER-SPECIFIC PROSTAGLANDINE1 POLYMERIC CONJUGATE", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 155, no. 01, 1 January 1997 (1997-01-01), NL, pages 65 - 74, XP002926547, ISSN: 0378-5173, DOI: 10.1016/S0378-5173(97)00159-2 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8436026B2 (en) | 2002-10-10 | 2013-05-07 | Ono Pharmaceutical Co., Ltd. | Endogeneous repair factor production promoters |
US8642630B2 (en) | 2002-10-10 | 2014-02-04 | Ono Pharmaceutical Co., Ltd. | Endogeneous repair factor production accelerators |
WO2006115293A1 (ja) * | 2005-04-22 | 2006-11-02 | The University Of Tokyo | pH応答性高分子ミセルの調製に用いる新規ブロック共重合体及びその製造法 |
JPWO2006115293A1 (ja) * | 2005-04-22 | 2008-12-18 | 国立大学法人 東京大学 | pH応答性高分子ミセルの調製に用いる新規ブロック共重合体及びその製造法 |
JP2007191643A (ja) * | 2006-01-20 | 2007-08-02 | Mitsui Chemicals Inc | 生体への定着性が付与されたポリアミノ酸誘導体 |
WO2008007650A1 (fr) * | 2006-07-14 | 2008-01-17 | Otsuka Chemical Co., Ltd. | résine d'accumulation de l'hydrazine |
JP5398261B2 (ja) * | 2006-07-14 | 2014-01-29 | 大塚化学株式会社 | ヒドラジンの貯蔵方法 |
JP2016520124A (ja) * | 2013-05-27 | 2016-07-11 | バイオリーダーズ コーポレーションBioleaders Corporation | ポリ−γ−グルタミン酸を含有する粘液分散または水和用組成物 |
JP2016520123A (ja) * | 2013-05-31 | 2016-07-11 | バイオリーダーズ コーポレーションBioleaders Corporation | 粘膜粘着性ポリ−γ−グルタミン酸ナノミセルおよびこれを用いた薬物伝達体 |
Also Published As
Publication number | Publication date |
---|---|
US20030104989A1 (en) | 2003-06-05 |
US6500916B1 (en) | 2002-12-31 |
KR20010041358A (ko) | 2001-05-15 |
EP1065233A1 (en) | 2001-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1496076B1 (en) | Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound | |
CN103755949B (zh) | 多臂聚乙二醇衍生物及其与药物的结合物和凝胶 | |
JP4566194B2 (ja) | タンパク質の誘導体化及び結合のためのシアル酸誘導体 | |
US8784849B2 (en) | Hydroxyapatite-targeting poly(ethylene glycol) and related polymers | |
AU649416B2 (en) | Glycosaminoglycan-modified protein | |
JP5349318B2 (ja) | ステロイド類の高分子結合体 | |
WO1999043736A1 (fr) | Polymeres transporteurs migrant dans des organes cibles et polymeres contenant des medicaments | |
US6242482B1 (en) | Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure | |
EP1164846A1 (en) | Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension | |
JPH07196925A (ja) | Pegヒドラゾンおよびpegオキシム結合形成試薬およびそれらのタンパク質誘導体 | |
EP0807115A4 (en) | MEDICAMENTS BASED ON POLYMERS WITH HIGH MOLECULAR WEIGHT | |
JPWO2009116509A1 (ja) | 生理活性物質の高分子結合体 | |
US5994495A (en) | Selectively functionalizable desdendrimers | |
JP3390965B2 (ja) | 糖結合スフィンゴシンを含有するポリマー化合物 | |
US20030108512A1 (en) | Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the treatment of cancer | |
US20030103934A1 (en) | Drugs having long-term retention in target tissue | |
JP2002508758A (ja) | 生物的に活性な材料 | |
JP2021176932A (ja) | カルボキシ化分解性ポリロタキサン及びその製造方法 | |
US7708978B2 (en) | Targeted hydrophilic polymer, binders with interferon and medical composite comprising above binders | |
WO2022102608A1 (ja) | ポリ(エチレングリコール)とポリ(l-アミノ酸誘導体)を含む共重合体、それらの微粒子および医薬組成物における使用 | |
JPH0692870A (ja) | 薬物担体用高分子および徐放性制ガン剤 | |
JPH07228688A (ja) | 糖修飾ポリ−ω−置換−L−グルタミン酸誘導体およびその製造方法 | |
KR20190099417A (ko) | 글루코오스-민감성 펩티드 호르몬 | |
JPH0782291A (ja) | 水溶性アンスラサイクリン誘導体 | |
FR3021660A1 (fr) | Copolymeres de formule (i) et utilisations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020007009474 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999906483 Country of ref document: EP Ref document number: 09623136 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999906483 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007009474 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020007009474 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999906483 Country of ref document: EP |